<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 的股价在周五下跌了 2.9%。该公司股价最低触及 48.87 美元，最后交易价为 49.92 美元。在交易过程中，共成交 24,034,551 股，较平均交易量 18,134,518 股增加了 33%。该股票之前的收盘价为 51.40 美元。</p>
<p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>Hims &amp; Hers 股票因基本面和挤压潜力而上涨</li>
</ul>
<p>多家券商对 HIMS 发布了报告。花旗集团重申了 &#34;卖出&#34; 评级，并在周二发布了 30.00 美元的目标价（上调自 25.00 美元）。Truist Financial 将 Hims &amp; Hers Health 的目标价从 39.00 美元下调至 33.00 美元，并在 4 月 10 日的研究报告中给予该公司 &#34;持有&#34; 评级。美国银行在 4 月 29 日的报告中将 Hims &amp; Hers Health 的目标价从 22.00 美元上调至 26.00 美元，并给予该股票 &#34;表现不佳&#34; 的评级。Leerink Partners 在 2 月 25 日的研究报告中将 Hims &amp; Hers Health 的目标价从 24.00 美元上调至 40.00 美元，并给予该股票 &#34;市场表现&#34; 的评级。最后，Canaccord Genuity Group 在 2 月 19 日的报告中将 Hims &amp; Hers Health 的目标价从 38.00 美元上调至 68.00 美元，并给予该公司 &#34;买入&#34; 评级。两位投资分析师对该股票给予了卖出评级，八位分析师给予了持有评级，三位分析师给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;持有&#34;，平均目标价为 37.67 美元。</p>
<p><strong>阅读我们对 Hims &amp; Hers Health 的最新分析</strong></p>
<h2>Hims &amp; Hers Health 价格表现</h2>
<ul>
<li>Hims &amp; Hers 股票因与诺和诺德的合作而飙升</li>
</ul>
<p>该股票的 50 日移动平均线为 32.74 美元，200 日移动平均线为 32.16 美元。该股票的市值为 113.1 亿美元，市盈率为 115.73，贝塔值为 1.84。</p>
<p>Hims &amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近在 5 月 5 日发布了季度财报。该公司报告季度每股收益为 0.20 美元，超出分析师一致预期的 0.12 美元，超出幅度为 0.08 美元。Hims &amp; Hers Health 的股本回报率为 10.97%，净利润率为 8.19%。该公司在本季度的收入为 5.8601 亿美元，而分析师预期为 5.3521 亿美元。去年同期，该公司每股收益为 0.05 美元。与去年同期相比，该公司的季度收入增长了 110.7%。分析师预计 Hims &amp; Hers Health, Inc. 本年度将发布 0.29 美元的每股收益。</p>
<h2>内部买卖情况</h2>
<ul>
<li>Hims 的减肥扩展：真正的增长还是仅仅是炒作？</li>
</ul>
<p>在其他新闻中，内部人士 Michael Chi 于 2 月 10 日星期一出售了 7,259 股该公司的股票。股票以平均价格 43.28 美元出售，总交易额为 314,169.52 美元。交易完成后，该内部人士现在直接持有 193,601 股公司股票，价值 8,379,051.28 美元。此交易代表其持股减少了 3.61%。该出售在与证券交易委员会的法律文件中披露，文件可通过 SEC 网站获取。此外，内部人士 Soleil Boughton 于 2 月 18 日星期二出售了 4,152 股公司的股票。该股票以平均价格 60.69 美元出售，总价值为 251,984.88 美元。出售后，该内部人士现在持有 157,345 股公司股票，价值 9,549,268.05 美元。该交易代表其持股减少了 2.57%。该出售的披露信息可以在此找到。内部人士在上个季度出售了价值 25,790,311 美元的 650,500 股公司股票。17.71% 的股票由公司内部人士持有。</p>
<h2>对 Hims &amp; Hers Health 的对冲基金看法</h2>
<p>对冲基金最近买入和卖出了该公司的股票。Means Investment CO. Inc. 在第四季度将其在 Hims &amp; Hers Health 的持股增加了 23.5%。Means Investment CO. Inc. 现在持有 50,040 股公司股票，价值 1,210,000 美元，在上个季度又购买了 9,508 股。Raymond James Financial Inc. 在第四季度获得了 Hims &amp; Hers Health 的新头寸，价值约 18,048,000 美元。阿拉斯加州财政部在第四季度购买了 Hims &amp; Hers Health 的新股份，价值约 2,628,000 美元。Pacer Advisors Inc. 在第四季度获得了 Hims &amp; Hers Health 的新股份，价值约 374,000 美元。最后，Genesee Capital Advisors LLC 在第四季度获得了 Hims &amp; Hers Health 的新头寸，价值 889,000 美元。63.52% 的股票由机构投资者持有。</p>
<h2>关于 Hims &amp; Hers Health</h2>
<p>(获取免费报告)</p>
<p>Hims &amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病学和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票超过 Hims &amp; Hers Health</li>
<li>三只值得购买和持有的医疗保健分红股票</li>
<li>谷歌在核反应堆上大举投资——你应该投资吗？</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>台湾半导体因芯片限制而有新的上涨理由</li>
<li>三只天然气股票提供优厚的分红收益</li>
<li>为什么近 20 位分析师在财报后上调 Meta 目标价</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

<p>Hims & Hers Health（纽约证券交易所代码：HIMS）的股价下跌了 2.9%，至 49.92 美元，交易量增加了 33%。分析师的评级意见不一，花旗集团维持 “卖出” 评级，目标价为 30 美元，而 Canaccord Genuity 将目标价上调至 68 美元，并给予 “买入” 评级。该公司报告的季度每股收益为 0.20 美元，超出预期，营收同比增长了 110.7%。内部交易活动中，高管进行了大量股票出售，对冲基金也在积极买入和卖出股票</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price traded down 2.9% on Friday . The company traded as low as $48.87 and last traded at $49.92. 24,034,551 shares changed hands during trading, an increase of 33% from the average session volume of 18,134,518 shares. The stock had previously closed at $51.40.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 的股价在周五下跌了 2.9%。该公司股价最低触及 48.87 美元，最后交易价为 49.92 美元。在交易过程中，共成交 24,034,551 股，较平均交易量 18,134,518 股增加了 33%。该股票之前的收盘价为 51.40 美元。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Hims &amp; Hers Stock Rises on Fundamentals and Squeeze Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers 股票因基本面和挤压潜力而上涨</li>
</ul>
</div><p>A number of brokerages have issued reports on HIMS. Citigroup reaffirmed a &#34;sell&#34; rating and issued a $30.00 target price (up from $25.00) on shares of Hims &amp; Hers Health in a research note on Tuesday. Truist Financial lowered their price objective on shares of Hims &amp; Hers Health from $39.00 to $33.00 and set a &#34;hold&#34; rating for the company in a research note on Thursday, April 10th. Bank of America boosted their price target on shares of Hims &amp; Hers Health from $22.00 to $26.00 and gave the stock an &#34;underperform&#34; rating in a report on Tuesday, April 29th. Leerink Partners raised their price objective on shares of Hims &amp; Hers Health from $24.00 to $40.00 and gave the stock a &#34;market perform&#34; rating in a research report on Tuesday, February 25th. Finally, Canaccord Genuity Group raised their target price on Hims &amp; Hers Health from $38.00 to $68.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and an average target price of $37.67.</p>
<div class="lb-trans"><p>多家券商对 HIMS 发布了报告。花旗集团重申了 &#34;卖出&#34; 评级，并在周二发布了 30.00 美元的目标价（上调自 25.00 美元）。Truist Financial 将 Hims &amp; Hers Health 的目标价从 39.00 美元下调至 33.00 美元，并在 4 月 10 日的研究报告中给予该公司 &#34;持有&#34; 评级。美国银行在 4 月 29 日的报告中将 Hims &amp; Hers Health 的目标价从 22.00 美元上调至 26.00 美元，并给予该股票 &#34;表现不佳&#34; 的评级。Leerink Partners 在 2 月 25 日的研究报告中将 Hims &amp; Hers Health 的目标价从 24.00 美元上调至 40.00 美元，并给予该股票 &#34;市场表现&#34; 的评级。最后，Canaccord Genuity Group 在 2 月 19 日的报告中将 Hims &amp; Hers Health 的目标价从 38.00 美元上调至 68.00 美元，并给予该公司 &#34;买入&#34; 评级。两位投资分析师对该股票给予了卖出评级，八位分析师给予了持有评级，三位分析师给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 &#34;持有&#34;，平均目标价为 37.67 美元。</p>
</div><p><strong>Read Our Latest Analysis on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Hims &amp; Hers Health 的最新分析</strong></p>
</div><h2>Hims &amp; Hers Health Price Performance</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 价格表现</h2>
</div><ul>
<li>Hims &amp; Hers Stock Soars on Novo Nordisk Collaboration</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers 股票因与诺和诺德的合作而飙升</li>
</ul>
</div><p>The stock's fifty day moving average is $32.74 and its two-hundred day moving average is $32.16. The stock has a market capitalization of $11.31 billion, a P/E ratio of 115.73 and a beta of 1.84.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 32.74 美元，200 日移动平均线为 32.16 美元。该股票的市值为 113.1 亿美元，市盈率为 115.73，贝塔值为 1.84。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims &amp; Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same period in the previous year, the company earned $0.05 earnings per share. The company's quarterly revenue was up 110.7% compared to the same quarter last year. Analysts expect that Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近在 5 月 5 日发布了季度财报。该公司报告季度每股收益为 0.20 美元，超出分析师一致预期的 0.12 美元，超出幅度为 0.08 美元。Hims &amp; Hers Health 的股本回报率为 10.97%，净利润率为 8.19%。该公司在本季度的收入为 5.8601 亿美元，而分析师预期为 5.3521 亿美元。去年同期，该公司每股收益为 0.05 美元。与去年同期相比，该公司的季度收入增长了 110.7%。分析师预计 Hims &amp; Hers Health, Inc. 本年度将发布 0.29 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><ul>
<li>Hims’ Weight Loss Expansion: Real Growth or Just Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims 的减肥扩展：真正的增长还是仅仅是炒作？</li>
</ul>
</div><p>In other news, insider Michael Chi sold 7,259 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $43.28, for a total transaction of $314,169.52. Following the completion of the transaction, the insider now directly owns 193,601 shares of the company's stock, valued at $8,379,051.28. This trade represents a 3.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. The trade was a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 650,500 shares of company stock worth $25,790,311 in the last quarter. 17.71% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，内部人士 Michael Chi 于 2 月 10 日星期一出售了 7,259 股该公司的股票。股票以平均价格 43.28 美元出售，总交易额为 314,169.52 美元。交易完成后，该内部人士现在直接持有 193,601 股公司股票，价值 8,379,051.28 美元。此交易代表其持股减少了 3.61%。该出售在与证券交易委员会的法律文件中披露，文件可通过 SEC 网站获取。此外，内部人士 Soleil Boughton 于 2 月 18 日星期二出售了 4,152 股公司的股票。该股票以平均价格 60.69 美元出售，总价值为 251,984.88 美元。出售后，该内部人士现在持有 157,345 股公司股票，价值 9,549,268.05 美元。该交易代表其持股减少了 2.57%。该出售的披露信息可以在此找到。内部人士在上个季度出售了价值 25,790,311 美元的 650,500 股公司股票。17.71% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>对 Hims &amp; Hers Health 的对冲基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the business. Means Investment CO. Inc. grew its stake in Hims &amp; Hers Health by 23.5% during the fourth quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock worth $1,210,000 after buying an additional 9,508 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Hims &amp; Hers Health in the 4th quarter worth approximately $18,048,000. State of Alaska Department of Revenue bought a new stake in Hims &amp; Hers Health in the fourth quarter worth approximately $2,628,000. Pacer Advisors Inc. acquired a new stake in shares of Hims &amp; Hers Health during the 4th quarter worth approximately $374,000. Finally, Genesee Capital Advisors LLC acquired a new position in shares of Hims &amp; Hers Health during the 4th quarter valued at $889,000. 63.52% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近买入和卖出了该公司的股票。Means Investment CO. Inc. 在第四季度将其在 Hims &amp; Hers Health 的持股增加了 23.5%。Means Investment CO. Inc. 现在持有 50,040 股公司股票，价值 1,210,000 美元，在上个季度又购买了 9,508 股。Raymond James Financial Inc. 在第四季度获得了 Hims &amp; Hers Health 的新头寸，价值约 18,048,000 美元。阿拉斯加州财政部在第四季度购买了 Hims &amp; Hers Health 的新股份，价值约 2,628,000 美元。Pacer Advisors Inc. 在第四季度获得了 Hims &amp; Hers Health 的新股份，价值约 374,000 美元。最后，Genesee Capital Advisors LLC 在第四季度获得了 Hims &amp; Hers Health 的新头寸，价值 889,000 美元。63.52% 的股票由机构投资者持有。</p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc. 运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病学和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Google Is Betting Big on Nuclear Reactors—Should You?</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票超过 Hims &amp; Hers Health</li>
<li>三只值得购买和持有的医疗保健分红股票</li>
<li>谷歌在核反应堆上大举投资——你应该投资吗？</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>台湾半导体因芯片限制而有新的上涨理由</li>
<li>三只天然气股票提供优厚的分红收益</li>
<li>为什么近 20 位分析师在财报后上调 Meta 目标价</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hims & Hers Health (NYSE:HIMS) 股价下跌 2.9% - 现在是卖出的时候吗？